SciSparc Ltd. Signs Exclusive License Agreement with Polyrizon for Cannabinoid-Based Pain Therapy
Aug 20, 2024
Scisparc Invest Information
SciSparc Advances Autism Spectrum Disorder Treatment with SCI-210 Clinical Trial Progression
Mar 1, 2024
SciSparc Ltd. (NASDAQ:SPRC) Soars on Positive Clinical Trial Launch
Nov 25, 2023
SciSparc Ltd. Embarks on Transformative Phase IIb Trial for Tourette Syndrome Using THC-Based Medication
Nov 11, 2023